Luy Ing Yan
Director/Board Member chez MICROPORT CARDIOFLOW MEDTECH CORPORATION
Fortune : 83 183 $ au 31/03/2024
Profil
Luy Ing Yan is currently an Executive Director at Shanghai MicroPort CardioFlow Medtech Co., Ltd.
and an Executive Director & VP-Regulatory Affairs at MicroPort CardioFlow Medtech Corp.
She completed her undergraduate and graduate degrees at Capital Medical University in 2004 and 2012, respectively.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
11/07/2023 | 576 137 ( 0,02% ) | 83 183 $ | 31/03/2024 |
Postes actifs de Luy Ing Yan
Sociétés | Poste | Début |
---|---|---|
MICROPORT CARDIOFLOW MEDTECH CORPORATION | Director/Board Member | 29/09/2020 |
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Shanghai MicroPort CardioFlow Medtech Co., Ltd. Medical SpecialtiesHealth Technology Part of MicroPort Scientific Corp., Shanghai MicroPort CardioFlow Medtech Co., Ltd. is a company headquartered in Shanghai, China. The firm designs, manufactures cardiac and orthopedic devices, functions as an investment holding & property management company. Jeffrey R. Lindstrom is the CEO, in this role since 2023. | Director/Board Member | 29/09/2020 |
Formation de Luy Ing Yan
Capital Medical University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
MICROPORT CARDIOFLOW MEDTECH CORPORATION | Health Technology |
Entreprise privées | 1 |
---|---|
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Shanghai MicroPort CardioFlow Medtech Co., Ltd. Medical SpecialtiesHealth Technology Part of MicroPort Scientific Corp., Shanghai MicroPort CardioFlow Medtech Co., Ltd. is a company headquartered in Shanghai, China. The firm designs, manufactures cardiac and orthopedic devices, functions as an investment holding & property management company. Jeffrey R. Lindstrom is the CEO, in this role since 2023. | Health Technology |